{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:19:00Z","timestamp":1758050340361,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.bulcan.2022.11.015","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T07:31:53Z","timestamp":1674891113000},"page":"320-330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Utilisation des tests g\u00e9nomiques en oncologie\u00a0: avis d\u2019experts Fran\u00e7ais selon la m\u00e9thode Delphi"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5881-9383","authenticated-orcid":false,"given":"Olivier","family":"Tr\u00e9dan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bulcan.2022.11.015_bib0210","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdx707","article-title":"The European Society for Medical Oncology (ESMO) Precision Medicine Glossary","volume":"29","author":"Yates","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2022.11.015_bib0215","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1002\/ijc.30691","article-title":"Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis","volume":"140","author":"Yang","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2022.11.015_bib0220","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ctrv.2016.11.011","article-title":"GEIS Guidelines for Gastrointestinal Sarcomas (GIST)","volume":"55","author":"Poveda","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"10.1016\/j.bulcan.2022.11.015_bib0225","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.bulcan.2022.11.015_bib0230","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Li\u00e8vre","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bulcan.2022.11.015_bib0235","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.critrevonc.2015.06.007","article-title":"Understanding next generation sequencing in oncology: a guide for oncologists","volume":"96","author":"Moorcraft","year":"2015","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.11.015_bib0240","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1309\/AJCP40XETVYAMJPY","article-title":"Comparison of next-generation sequencing and mutation-specific platforms in clinical practice","volume":"143","author":"Hinrichs","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.11.015_bib0245","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jmoldx.2016.06.004","article-title":"Comparison of next-generation sequencing panels and platforms for detection and verification of somatic tumor variants for clinical diagnostics","volume":"18","author":"Misyura","year":"2016","journal-title":"J Mol Diagn"},{"issue":"5","key":"10.1016\/j.bulcan.2022.11.015_bib0250","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s13402-014-0196-2","article-title":"Performance of Amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology","volume":"37","author":"Sie","year":"2014","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2022.11.015_bib0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13046-017-0591-4","article-title":"High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods","volume":"36","author":"Su","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bulcan.2022.11.015_bib0260","first-page":"1","article-title":"The Delphi Technique: making sense of consensus","volume":"12","author":"Hsu","year":"2007","journal-title":"Prac Assess Res Eval"},{"issue":"25","key":"10.1016\/j.bulcan.2022.11.015_bib0265","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","article-title":"American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review\u2013based consensus methodology","volume":"30","author":"Loblaw","year":"2012","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.bulcan.2022.11.015_bib0270","doi-asserted-by":"crossref","first-page":"e20476","DOI":"10.1371\/journal.pone.0020476","article-title":"Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review","volume":"6","author":"Boulkedid","year":"2011","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.bulcan.2022.11.015_bib0275","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.bulcan.2022.11.015_bib0280","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi Survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nursing"},{"issue":"10","key":"10.1016\/j.bulcan.2022.11.015_bib0285","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/ACM.0000000000001812","article-title":"The use of the Delphi and other consensus gro*up methods in medical education research: a review","volume":"92","author":"Humphrey-Murto","year":"2017","journal-title":"Acad Med"},{"issue":"10","key":"10.1016\/j.bulcan.2022.11.015_bib0290","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00345-019-02636-7","article-title":"Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi Consensus Project","volume":"37","author":"van Luijtelaar","year":"2019","journal-title":"World J Urol"},{"issue":"7","key":"10.1016\/j.bulcan.2022.11.015_bib0295","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s12094-020-02518-0","article-title":"Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus","volume":"23","author":"Isla","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2022.11.015_bib0300","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12094-016-1508-y","article-title":"Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi Study","volume":"19","author":"Gavila","year":"2017","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2022.11.015_bib0305","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/annonc\/mds645","article-title":"Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 Working Group Consensus Statement","volume":"24","author":"Azim","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2022.11.015_bib0310","doi-asserted-by":"crossref","DOI":"10.1007\/s13187-021-01956-w","article-title":"Core competencies in cancer genomics for healthcare professionals: results from a systematic literature review and a Delphi process","author":"Hoxhaj","year":"20223751332","journal-title":"J Canc Educ"},{"year":"2010","author":"Haute Autorit\u00e9 de sant\u00e9","series-title":"\u00c9laboration de Recommandations de Bonne Pratique. M\u00e9thode \u00ab\u00a0Recommandations Pour La Pratique Clinique\u00a0\u00bb","key":"10.1016\/j.bulcan.2022.11.015_bib0315"},{"issue":"2","key":"10.1016\/j.bulcan.2022.11.015_bib0320","first-page":"131","article-title":"Building a shared patient record for breast cancer management: a French Delphi Study","volume":"18","author":"Letrilliart","year":"2009","journal-title":"Eur J Cancer Care"},{"issue":"3","key":"10.1016\/j.bulcan.2022.11.015_bib0325","first-page":"655","article-title":"How to use the nominal group and Delphi techniques","volume":"38","author":"McMillan","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"10.1016\/j.bulcan.2022.11.015_bib0330","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s10545-018-0229-5","article-title":"Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphi-Based International Workshop","volume":"41","author":"Koene","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"10026","key":"10.1016\/j.bulcan.2022.11.015_bib0335","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2022.11.015_bib0340","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1038\/s41467-020-19342-3","article-title":"Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencing","volume":"11","author":"Lang","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bulcan.2022.11.015_bib0345","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13073-017-0408-2","article-title":"Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies","volume":"9","author":"Hartmaier","year":"2017","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.bulcan.2022.11.015_bib0350","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41571-018-0002-6","article-title":"The emerging clinical relevance of genomics in cancer medicine","volume":"15","author":"Berger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.11.015_bib0355","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/EDBK_100014","article-title":"Cancer of unknown primary site: new treatment paradigms in the era of precision medicine","volume":"38","author":"Hainsworth","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.bulcan.2022.11.015_bib0360","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12254-020-00578-0","article-title":"Molecular profiling in breast cancer\u2014ready for clinical routine?","volume":"13","author":"Tendl","year":"2020","journal-title":"memo"},{"issue":"1","key":"10.1016\/j.bulcan.2022.11.015_bib0365","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10549-017-4415-1","article-title":"Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers","volume":"166","author":"Santa-Maria","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"10.1016\/j.bulcan.2022.11.015_bib0370","article-title":"Lack of evidence to support large-panel genomic testing in treatment selection for malignant melanoma","volume":"38","author":"Dimitrova","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2022.11.015_bib0375","first-page":"1387","article-title":"NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications","volume":"18","author":"Forschner","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"doi-asserted-by":"crossref","unstructured":"Paratala B.S. Chung J.H., Williams C.B., Yilmazel B., Petrosky W., Williams K., et al. RET rearrangements are actionable alterations in breast cancer. Nat Commun 2018;9(1):4821. doi: 10.1038\/s41467-018-07341-4.","key":"10.1016\/j.bulcan.2022.11.015_bib0380","DOI":"10.1038\/s41467-018-07341-4"},{"doi-asserted-by":"crossref","unstructured":"Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. 2013;9. Oncogene 2014;33(1):1-9. doi: 10.1038\/onc.2013.34.","key":"10.1016\/j.bulcan.2022.11.015_bib0385","DOI":"10.1038\/onc.2013.34"},{"issue":"33","key":"10.1016\/j.bulcan.2022.11.015_bib0390","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted therapy in advanced melanoma with rare BRAF mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.11.015_bib0395","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fmolb.2020.00154","article-title":"Current state of target treatment in BRAF mutated melanoma","volume":"7","author":"Tanda","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"10","key":"10.1016\/j.bulcan.2022.11.015_bib0400","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3390\/cancers12102914","article-title":"Circulating tumor DNA testing opens new perspectives in melanoma management","volume":"12","author":"Sacco","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bulcan.2022.11.015_bib0405","first-page":"O.20.00522","article-title":"Circulating tumor DNA profiling from breast cancer screening through to metastatic disease","volume":"5","author":"Page","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.bulcan.2022.11.015_bib0205","doi-asserted-by":"crossref","first-page":"212540","DOI":"10.7573\/dic.212540","article-title":"Advances in the use of PARP inhibitor therapy for breast cancer","volume":"7","author":"McCann","year":"2018","journal-title":"Drugs Context"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123000280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:12Z","timestamp":1757792232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123000280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0007455123000280"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.11.015","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilisation des tests g\u00e9nomiques en oncologie\u00a0: avis d\u2019experts Fran\u00e7ais selon la m\u00e9thode Delphi","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}